95 related articles for article (PubMed ID: 27393472)
1. [Not Available].
; Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB
Therapie; 2011; 66(6):517-25. PubMed ID: 27393472
[TBL] [Abstract][Full Text] [Related]
2. [Update of the French drug reaction assessment method].
; Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB
Therapie; 2011; 66(6):517-25. PubMed ID: 22186077
[TBL] [Abstract][Full Text] [Related]
3. Updating the French method for the causality assessment of adverse drug reactions.
Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
[TBL] [Abstract][Full Text] [Related]
4. [Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities!].
Jonville-Bera AP; Gautier S; Micallef J; Massy N; Atzenhoffer M; Drici MD; Grandvuillemin A;
Therapie; 2023; 78(5):477-488. PubMed ID: 36890032
[TBL] [Abstract][Full Text] [Related]
5. [The congress of the French Society of Pharmacology and Therapeutics celebrate in Nancy, 20 April 2016, 40 years of French Regional Pharmacovigilance Centres!].
Jonville-Béra AP; Mallaret M; Sgro C;
Therapie; 2016 Sep; 71(4):351-4. PubMed ID: 27296805
[TBL] [Abstract][Full Text] [Related]
6. [The French pharmacovigilance system: structure and missions].
Welsch M; Alt M; Richard MH; Imbs JL
Presse Med; 2000 Jan; 29(2):102-6. PubMed ID: 10682040
[TBL] [Abstract][Full Text] [Related]
7. [From psychoactive medicines to addictovigilance in French Public Health Code (1990-2017)].
Baumevieille M; Perri-Plandé J; Miremont-Salamé G; Daveluy A; Haramburu F
Therapie; 2019 Jun; 74(3):375-382. PubMed ID: 30193805
[TBL] [Abstract][Full Text] [Related]
8. Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies.
Théophile H; Dutertre JP; Gérardin M; Valnet-Rabier MB; Bidault I; Guy C; Haramburu F; Hillaire-Buys D; Méglio C; Arimone Y
Therapie; 2015; 70(5):465-76. PubMed ID: 26423144
[TBL] [Abstract][Full Text] [Related]
9. [National Campaign of Vaccination against the flu A (H1N1)v: National Follow-up of Pharmacovigilance].
Durrieu G; Caillet C; Lacroix I; Jacquet A; Faucher A; Ouaret S; Sommet A; Perault-Pochat MC; Kreft-Jaïs C; Castot A; Damase-Michel C; Montastruc JL;
Therapie; 2011; 66(6):527-40. PubMed ID: 22186078
[TBL] [Abstract][Full Text] [Related]
10. Perioperative platelet transfusion: recommendations of the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS) 2003.
Samama CM; Djoudi R; Lecompte T; Nathan-Denizot N; Schved JF;
Can J Anaesth; 2005 Jan; 52(1):30-7. PubMed ID: 15625253
[TBL] [Abstract][Full Text] [Related]
11. Vigilance in industry: cosmetics and household cleaning products. Balance sheet of case report from 2005 to 2007.
Kornfeld-Lecanu S; Zajaczkowski F; Dubourg S; Martin L; Lefort S; Siest S
Clin Exp Dermatol; 2010 Dec; 35(8):874-80. PubMed ID: 20718782
[TBL] [Abstract][Full Text] [Related]
12. [Treatment recommendations for type 2 diabetes. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS)].
Diabetes Metab; 1999 Dec; 25 Suppl 6():1-79. PubMed ID: 10697746
[No Abstract] [Full Text] [Related]
13. Updates for the antibiotic treatment of legionellosis in adults. Agence française de sécurité sanitaire des produits de santé.
Dumarcet N;
Med Mal Infect; 2012 Sep; 42(9):393-403, 403-13. PubMed ID: 22921502
[No Abstract] [Full Text] [Related]
14. French Haemovigilance Data on Platelet Transfusion.
Willaert B; Vo Mai MP; Caldani C
Transfus Med Hemother; 2008; 35(2):118-121. PubMed ID: 21512639
[TBL] [Abstract][Full Text] [Related]
15. [Anti-ulcer agents: indications in adults. Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS)].
Ann Med Interne (Paris); 2000 Sep; 151(5):353-68. PubMed ID: 11033469
[No Abstract] [Full Text] [Related]
16. [Pharmaceutical development aimed at improving safety for children].
Andrieu V; Reynier JP
Therapie; 2004; 59(6):599-601. PubMed ID: 15789821
[TBL] [Abstract][Full Text] [Related]
17. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
Koh Y; Yap CW; Li SC
Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
[TBL] [Abstract][Full Text] [Related]
18. [Hypertensive events in adults. High blood pressure without organ involvement and hypertensive events requiring emergency care. Guidelines. Agence Française de Sécurité Sanitaire Des Produits de Santé].
Agence Française de Sécurité Sanitaire Des Produits de Santé (AFSSAPS)
J Mal Vasc; 2002 Oct; 27(4):234-8. PubMed ID: 12457131
[No Abstract] [Full Text] [Related]
19. Information sheets and informed consent forms for clinical study participants: towards standardised recommendations?
Chassany O; Bernard-Harlaut M; Guy G; Billon N
Therapie; 2009; 64(3):161-86. PubMed ID: 19671429
[TBL] [Abstract][Full Text] [Related]
20. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
Jaillon P
Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
